CD274 and lymphopenia: Importantly, its efficacy remains independent of intact immune function, presenting a distinct advantage over PD-L1 inhibitors, whose therapeutic effects may be compromised in patients with pre-existing immune dysfunction such as T-cell exhaustion and lymphopenia.